Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Osanetant for Hot Flashes in Men with Prostate Cancer
NCT05647447Phase 1Withdrawn
- Sponsor
- University of Kansas Medical Center
- Start
- Jan 2023
- Primary completion
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of osanetant in hot flashes, sponsored by University of Kansas Medical Center. Primary endpoint: Frequency and severity of vasomotor symptoms at 28 days. Planned start Jan 2023; status: withdrawn.
02
Drugs
osanetant
03
Conditions
hot flashes
Beyond the preview
Go deeper on NCT05647447.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05647447.